SlideShare ist ein Scribd-Unternehmen logo
1 von 1
Downloaden Sie, um offline zu lesen
RESEARCH POSTER PRESENTATION DESIGN © 2012
www.PosterPresentations.com
On both days of testing, participants were subject to the oculomotor portion of
the VNG assessment in addition to the spontaneous nystagmus assessment.
•  Spontaneous Nystagmus: Focus on target for 10 seconds, then maintain
gaze without fixation for 5 seconds.
•  Gaze Evoked Nystagmus: Focus on target presented 15o from midline for
10 seconds, then maintain gaze for 5 seconds without fixation. Repeat in
opposite direction.
•  Saccades: Track 24 randomly presented targets which appear at either 5, 10,
20, -5, -10, or -20 degrees from midline.
•  Smooth pursuit: Track at single target that passes repeatedly from left to
right at frequencies of .10, .30, and .50 Hz
•  Optokinetic nystagmus (OKN): Track targets in the center of a full-field
presentation, moving at rates of 20, 40, and 60 deg/sec in both the clockwise
and counterclockwise directions.
Following completion of both test sessions, participants completed a caffeine
withdrawal assessment to evaluate the degree to which they experienced
seven of the most common symptoms of caffeine withdrawal.
Participants
15 participants
• 18-65 years of age
• Normal visual acuity or corrected with contact lenses
• No history of dizziness or balance disorders, seizure, tumors, multiple
sclerosis, or cardio vascular disorders
Caffeine Intake Assessment
Prospective participants documented their caffeine consumption over a three-
day time period and specified the type and amount of caffeine consumed.
Individuals who were found to consume, on average, between 200 mg and 900
mg of caffeine per day were eligible to participate in the study.
Data Collection
Participants were assigned to one of two groups:
•  Group A: subject to oculomotor testing immediately after caffeine
consumption first, and once more after abstaining for 24 hours.
•  Group B: tested after abstaining from caffeine for 24 hours first, and again
immediately after caffeine consumption.
Many vestibular testing centers require patients to abruptly abstain from
caffeine intake prior to testing, a recommendation which does not appear to be
evidence based. This study will examine the validity and necessity of this
practice by investigating the effects of caffeine consumption and caffeine
withdrawal on the oculomotor portion of the vestibular test battery, using
videonystagmography. Findings that are in opposition to current test protocol
trends may lead to the reevaluation of these protocols, which may be causing
undue discomfort and inconvenience to the potential patient, and may also
be negatively impacting test results.
Caffeine is the most commonly used psychoactive drug in the world and is
consumed daily by 85% of the United States population (Mitchell, Knight,
Hockenberry, Teplansky, & Hartman, 2014; Nehlig, Daval, & Debry, 1992).
Pharmacodynamically, caffeine has very positively reinforcing effects,
however regular and heavy caffeine users may experience negative
physical effects from abruptly abstaining from caffeine; this manifestation
of symptoms is referred to as caffeine withdrawal. The following symptoms
have been associated with caffeine withdrawal: headache, fatigue, decreased
energy/activeness, decreased alertness, drowsiness, decreased
contentedness, depressed mood, difficulty concentrating, irritability, and
foggy headedness (Juliano & Griffiths, 2004).
Caffeine withdrawal can occur after daily consumption of as little as 100 mg of
caffeine; however, withdrawal symptoms tend to be more intense and more
frequently reported with heavier caffeine use (Evans & Griffiths, 1999).
Symptoms begin to occur between 6 and 43 hours after abstaining, with peak
symptoms occurring around 24 hours (Ozsungur, Brenner, & El-Sohemy,
2009).
Investigating the effect of caffeine on oculomotor assessment is an important
undertaking because the tests of oculomotor function are known to be
influenced by fatigue and inattention, as well as certain drugs that the patient
may be taking (Jacobson & Shephard, 2008). It is useful to know how the
fatigue and inattention associated with caffeine withdrawal may affect test
results, as well as how caffeine consumption affects test results in regular
users.
Introduction and Background
Methods
Results
Conclusions
•  For most measures of the VNG oculomotor assessment there is no
statistically significant difference in performance while under the
influence of caffeine and after 24 hours of abstention. On average, all
results fell within normal limits in both test conditions.
•  Statistically significant differences were discovered for 40 deg/sec OKN
performance, however, these differences would not be considered to be
clinically significant.
•  While 86% of participants reported experiencing caffeine withdrawal
symptoms of drowsiness/fatigue and 80% reported decreased alertness/
concentration, these symptoms do not appear to have had a clinically
significant impact on overall oculomotor assessment performance.
•  The recommendation to have patients abstain from caffeine prior to VNG
assessment does not appear to be necessary as caffeine did not produce a
clinically significant effect on oculomotor performance in this study.
Abrupt abstention from caffeine, however, does cause unpleasant caffeine
withdrawal symptoms which can be a source of undue stress for the potential
patient; these symptoms do not appear to significantly impact oculomotor
test performance.
References
-Evans, S. & Griffiths, R. (1999). Caffeine withdrawal: A parametric analysis of caffeine dosing
conditions. The Journal of Pharmacology and Experimental Therapeutics, 289(1), 285-294.
-Jacobson, G., & Shepard, N. (2008). Balance function assessment and management. San Diego, CA:
Plural Pub.
-Juliano, L.M. & Griffiths, R.R. (2004). A critical review of caffeine withdrawal: empirical validation
of symptoms and signs, incidence, severity, and associated features. Psychopharmacology, 176, 1-29.
-Mitchel, D.C., Knight, C.A., Hockenberry, J., Teplansky, R., & Hartman, T.J. (2014). Beverage
caffeine intakes in the U.S. Food and Chemical Toxicology, 63, 136-142.
-Nehlig, A., Daval, J., & Debry, G. (1992). Caffeine and the central nervous system: Mechanisms of
action, biochemical, metabolic and psychostimulant effects. Brain Research Reviews, 17, 139-170.
-Ozsungur, S., Brenner, D., El-Sohemy, A. (2009). Fourteen well-described caffeine withdrawal
symptoms facts into three clusters. Psychopharmacology, 201, 541-548
Department of Hearing, Speech, and Language Sciences – Gallaudet University, Washington, DC
Krystyna N. Graham, M.S., and Chizuko Tamaki, Au.D., Ph.D
The Effect of Caffeine Withdrawal on VNG Oculomotor Assessment*
4.95	
  
2.19	
  
4.90	
  
5.28	
  
1.57	
  
3.38	
  
0.00	
  
1.00	
  
2.00	
  
3.00	
  
4.00	
  
5.00	
  
6.00	
  
.10	
  Hz	
   .30	
  Hz	
   .50	
  Hz	
  
Average	
  Velocity	
  Gain	
  Asymmetry	
  (%)	
  
Target	
  Frequency	
  
Caffeinated	
  	
  vs.	
  AbstenIon	
  
Smooth	
  Pursuit	
  Asymmetry	
  
Caffeinated	
   Absten/on	
  
Results
0.18	
  
0.17	
   0.18	
  
0.18	
  
0.18	
  
0.18	
  0.18	
  
0.17	
   0.17	
  
0.23	
  
0.17	
   0.17	
  
0.00	
  
0.05	
  
0.10	
  
0.15	
  
0.20	
  
0.25	
  
5	
   10	
   20	
   -­‐5	
   -­‐10	
   20	
  
Average	
  Saccade	
  Latency	
  (sec)	
  
Target	
  Movement	
  from	
  Midline	
  (Degrees)	
  
Caffeinated	
  	
  vs.	
  AbstenIon	
  	
  
Saccade	
  Latency	
  
Caffeinated	
   Absten/on	
  
*Approved by the Gallaudet Institutional Review Board (IRB)
Methods Results
Figure 1. Comparison of overall saccade accuracy at each degree of target displacement, with caffeine
and after abstention. Yellow circles indicate nearly statistical significant differences for the specified
parameter (p =.086 for 10 degrees, p =.063 for -5 degrees).
Figure 2. Comparison average saccade latency at each degree of target displacement, with
caffeine and after abstention. Yellow circle indicates a nearly statistically significant difference
for the specified parameter (p= .066 for -10 degrees).
Figure 3. Average smooth pursuit velocity gain for rightward and leftward eye movements,
with caffeine and after abstention. Yellow circle indicates a nearly statistically significant
difference for the specified parameter (p =.089 for rightward gain at .10 Hz).
Figure 4. Smooth pursuit velocity gain asymmetry, with caffeine and after abstention, in
response to tracking sinusoidal targets presented at .10, .30, and .50 Hz.
Figure 6. Average velocity gain of optokinetic nystagmus, with caffeine and after abstention,
in response to clockwise and counterclockwise rotating stimuli presented at 20, 40, and 60 deg/
sec. Green circle indicates statistically significant difference for the specified parameter
(p = .041 for 40 deg/sec clockwise stimuli).
Figure 5. Graphic representation of the average velocity of optokinetic nystagmus, with
caffeine and after abstention, in response to clockwise and counterclockwise rotating stimuli
presented 20, 40, and 60 deg/sec. Green circles indicate statistically significant differences
for the specified parameters (p = .009 for 40 deg/sec clockwise; p = .013 for 40 deg/sec
counterclockwise).
22.71	
  
37.63	
  
40.27	
  
20.26	
  
32.85	
  
35.53	
  
23.43	
  
34.18	
  
37.53	
  
17.40	
  
29.63	
  
33.41	
  
0.00	
  
5.00	
  
10.00	
  
15.00	
  
20.00	
  
25.00	
  
30.00	
  
35.00	
  
40.00	
  
45.00	
  
20	
  Deg/Sec	
   40	
  Deg/Sec	
   60	
  Deg/Sec	
   20	
  Deg/Sec	
   40	
  Deg/Sec	
   60	
  Deg/Sec	
  
Clock	
  Wise	
  S/mulus	
   Counterclockwise	
  S/mulus	
  
Average	
  Velocity	
  (Deg/Sec)	
  	
  
Caffeinated	
  vs.	
  AbstenIon	
  
OKN	
  Velocity	
  	
  
Caffeinated	
  
Absten/on	
  
1.00	
  
0.85	
  
0.60	
  
1.00	
  
0.81	
  
0.58	
  
0.75	
  
0.55	
  
0.75	
  
0.57	
  
0	
  
0.2	
  
0.4	
  
0.6	
  
0.8	
  
1	
  
1.2	
  
20	
  Deg/Sec	
   40	
  Deg/Sec	
   60	
  Deg/Sec	
   20	
  Deg/Sec	
   40	
  Deg/Sec	
   60	
  Deg/Sec	
  
Clock	
  Wise	
  S/mulus	
   Counterclockwise	
  S/mulus	
  
Average	
  Velocity	
  Gain	
  
Caffeinated	
  vs.	
  AbstenIon	
  
OKN	
  Gain	
  
Caffeinated	
  
Absten/on	
  
0.93	
  
0.96	
  
0.91	
  
0.95	
  
0.97	
  
0.90	
  0.90	
  
0.98	
  
0.96	
  
0.92	
  
0.98	
  
0.94	
  
0.86	
  
0.88	
  
0.9	
  
0.92	
  
0.94	
  
0.96	
  
0.98	
  
1	
  
.10	
  Hz	
   .30	
  Hz	
   .50	
  Hz	
   .10	
  Hz	
   .30	
  Hz	
   .50	
  Hz	
  
Gain	
  LeU	
  	
   Gain	
  Right	
  
Average	
  Velocity	
  Gain	
  	
  
Caffeinated	
  	
  vs.	
  AbstenIon	
  
Smooth	
  Pursuit	
  Velocity	
  Gain	
  	
  
Caffeinated	
   Absten/on	
  
96.91	
  
102.52	
  
95.13	
  
98.70	
  
97.29	
   97.05	
  
99.80	
  
97.74	
  
94.80	
  
96.42	
  
98.99	
  
97.96	
  
90.00	
  
92.00	
  
94.00	
  
96.00	
  
98.00	
  
100.00	
  
102.00	
  
104.00	
  
5	
   10	
   20	
   -­‐5	
   -­‐10	
   -­‐20	
  
Overall	
  Accuracy	
  (%)	
  
Target	
  Movement	
  from	
  Midline	
  (Degrees)	
  
Caffeinated	
  	
  vs.	
  AbstenIon	
  	
  
	
  Saccade	
  Accuracy	
  
Caffeinated	
   Absten/on	
  
0	
   2	
   4	
   6	
   8	
   10	
   12	
   14	
   16	
  
Normal	
  
Sqaurewave	
  Jerk	
  
DriU	
  
Normal	
  
Sqaurewave	
  Jerk	
  
DriU	
  
Absten/on	
  Caffeinated	
  
Total	
  Number	
  of	
  ParIcipants	
  
QualitaIve	
  Finding	
  
FixaIon	
  On	
  
Spontaneous	
  
Gaze	
  LeU	
  
Gaze	
  Right	
  
0	
   2	
   4	
   6	
   8	
   10	
   12	
   14	
   16	
  
Normal	
  
Sqaurewave	
  Jerk	
  
DriU	
  
Normal	
  
Sqaurewave	
  Jerk	
  
DriU	
  
Absten/on	
  Caffeinated	
  
Total	
  Number	
  of	
  ParIcipants	
  
QualitaIve	
  Finding	
  
FixaIon	
  Off	
  
Spontaneous	
  
Gaze	
  LeU	
  
Gaze	
  Right	
  
Figure 7a. Qualitative results of gaze and spontaneous
evoked nystagmus assessments with fixation light on,
caffeinated and after abstention.
Figure 7b. Qualitative results of gaze and spontaneous
evoked nystagmus assessments with fixation light off,
caffeinated and after abstention.
Figure 8. Caffeine withdrawal assessment responses.

Weitere ähnliche Inhalte

Was ist angesagt?

Virtual Reality Reflection Therapy Improves Balance and Gait in Patients with...
Virtual Reality Reflection Therapy Improves Balance and Gait in Patients with...Virtual Reality Reflection Therapy Improves Balance and Gait in Patients with...
Virtual Reality Reflection Therapy Improves Balance and Gait in Patients with...Avi Dey
 
Does it matter how congestion is relieved
Does it matter how congestion is relievedDoes it matter how congestion is relieved
Does it matter how congestion is relieveddrucsamal
 
early Mobility in ICU
early Mobility in ICUearly Mobility in ICU
early Mobility in ICUnikita das
 
OutlineOfReap1999-2015
OutlineOfReap1999-2015OutlineOfReap1999-2015
OutlineOfReap1999-2015cimal
 
Patient Controlled Analgesia: Return to Nursing Program
Patient Controlled Analgesia: Return to Nursing ProgramPatient Controlled Analgesia: Return to Nursing Program
Patient Controlled Analgesia: Return to Nursing ProgramIHNA Australia
 
The Effectiveness of Mirror Therapy with Stroke Patients in Producing Improve...
The Effectiveness of Mirror Therapy with Stroke Patients in Producing Improve...The Effectiveness of Mirror Therapy with Stroke Patients in Producing Improve...
The Effectiveness of Mirror Therapy with Stroke Patients in Producing Improve...CrimsonPublishersTNN
 
Case presentation (lab analytical quality assurance problem )
Case presentation (lab analytical quality assurance problem )Case presentation (lab analytical quality assurance problem )
Case presentation (lab analytical quality assurance problem )Rania Elsharkawy
 
REG Interstitial Lung Disease Working Group Meeting
REG Interstitial Lung Disease Working Group MeetingREG Interstitial Lung Disease Working Group Meeting
REG Interstitial Lung Disease Working Group MeetingZoe Mitchell
 
Weeks_case study final
Weeks_case study finalWeeks_case study final
Weeks_case study finalAllison Weeks
 
1997 practice parameters for the indications for polysomnography and relate...
1997   practice parameters for the indications for polysomnography and relate...1997   practice parameters for the indications for polysomnography and relate...
1997 practice parameters for the indications for polysomnography and relate...alpha314
 
Mirror therapy practical protocol for stroke rehabilitation (2013)
Mirror therapy   practical protocol for stroke rehabilitation (2013)Mirror therapy   practical protocol for stroke rehabilitation (2013)
Mirror therapy practical protocol for stroke rehabilitation (2013)Andres Salazar
 
Pmr buzz magazine april 2021
Pmr buzz magazine april 2021Pmr buzz magazine april 2021
Pmr buzz magazine april 2021mrinal joshi
 
Ct and mri findings chief complaint of headache
Ct and mri findings chief complaint of headacheCt and mri findings chief complaint of headache
Ct and mri findings chief complaint of headacheUosum
 
Selective Attention Research
Selective Attention ResearchSelective Attention Research
Selective Attention ResearchNicholas Lopez
 
ATS Symposium: Leukotriene Antagonists As First-line Asthma Controller For St...
ATS Symposium: Leukotriene Antagonists As First-line Asthma Controller For St...ATS Symposium: Leukotriene Antagonists As First-line Asthma Controller For St...
ATS Symposium: Leukotriene Antagonists As First-line Asthma Controller For St...Zoe Mitchell
 
ICN Victoria: Gantner on "Translating Research into Practice"
ICN Victoria: Gantner on "Translating Research into Practice"ICN Victoria: Gantner on "Translating Research into Practice"
ICN Victoria: Gantner on "Translating Research into Practice"Intensive Care Network Victoria
 

Was ist angesagt? (20)

Virtual Reality Reflection Therapy Improves Balance and Gait in Patients with...
Virtual Reality Reflection Therapy Improves Balance and Gait in Patients with...Virtual Reality Reflection Therapy Improves Balance and Gait in Patients with...
Virtual Reality Reflection Therapy Improves Balance and Gait in Patients with...
 
Concussion Presentation
Concussion PresentationConcussion Presentation
Concussion Presentation
 
Does it matter how congestion is relieved
Does it matter how congestion is relievedDoes it matter how congestion is relieved
Does it matter how congestion is relieved
 
early Mobility in ICU
early Mobility in ICUearly Mobility in ICU
early Mobility in ICU
 
Stroke Rehabilitation :Physiotherapy
Stroke Rehabilitation :PhysiotherapyStroke Rehabilitation :Physiotherapy
Stroke Rehabilitation :Physiotherapy
 
OutlineOfReap1999-2015
OutlineOfReap1999-2015OutlineOfReap1999-2015
OutlineOfReap1999-2015
 
Patient Controlled Analgesia: Return to Nursing Program
Patient Controlled Analgesia: Return to Nursing ProgramPatient Controlled Analgesia: Return to Nursing Program
Patient Controlled Analgesia: Return to Nursing Program
 
The Effectiveness of Mirror Therapy with Stroke Patients in Producing Improve...
The Effectiveness of Mirror Therapy with Stroke Patients in Producing Improve...The Effectiveness of Mirror Therapy with Stroke Patients in Producing Improve...
The Effectiveness of Mirror Therapy with Stroke Patients in Producing Improve...
 
Journal club
Journal clubJournal club
Journal club
 
Case presentation (lab analytical quality assurance problem )
Case presentation (lab analytical quality assurance problem )Case presentation (lab analytical quality assurance problem )
Case presentation (lab analytical quality assurance problem )
 
REG Interstitial Lung Disease Working Group Meeting
REG Interstitial Lung Disease Working Group MeetingREG Interstitial Lung Disease Working Group Meeting
REG Interstitial Lung Disease Working Group Meeting
 
Weeks_case study final
Weeks_case study finalWeeks_case study final
Weeks_case study final
 
1997 practice parameters for the indications for polysomnography and relate...
1997   practice parameters for the indications for polysomnography and relate...1997   practice parameters for the indications for polysomnography and relate...
1997 practice parameters for the indications for polysomnography and relate...
 
Mirror therapy practical protocol for stroke rehabilitation (2013)
Mirror therapy   practical protocol for stroke rehabilitation (2013)Mirror therapy   practical protocol for stroke rehabilitation (2013)
Mirror therapy practical protocol for stroke rehabilitation (2013)
 
Pmr buzz magazine april 2021
Pmr buzz magazine april 2021Pmr buzz magazine april 2021
Pmr buzz magazine april 2021
 
Ct and mri findings chief complaint of headache
Ct and mri findings chief complaint of headacheCt and mri findings chief complaint of headache
Ct and mri findings chief complaint of headache
 
Selective Attention Research
Selective Attention ResearchSelective Attention Research
Selective Attention Research
 
ATS Symposium: Leukotriene Antagonists As First-line Asthma Controller For St...
ATS Symposium: Leukotriene Antagonists As First-line Asthma Controller For St...ATS Symposium: Leukotriene Antagonists As First-line Asthma Controller For St...
ATS Symposium: Leukotriene Antagonists As First-line Asthma Controller For St...
 
ICN Victoria: Gantner on "Translating Research into Practice"
ICN Victoria: Gantner on "Translating Research into Practice"ICN Victoria: Gantner on "Translating Research into Practice"
ICN Victoria: Gantner on "Translating Research into Practice"
 
Diabetic eye care 2017
Diabetic eye care 2017Diabetic eye care 2017
Diabetic eye care 2017
 

Andere mochten auch

Poster presentation
Poster presentationPoster presentation
Poster presentationGareth Fenn
 
Monika Kopf_Abstract
Monika Kopf_AbstractMonika Kopf_Abstract
Monika Kopf_AbstractMonika Köpf
 
PosterPresentations
PosterPresentationsPosterPresentations
PosterPresentationsSaad Khan
 
Sbrt Volumetric Analysis
Sbrt Volumetric AnalysisSbrt Volumetric Analysis
Sbrt Volumetric Analysiscjhampton
 
SBRT Dosimetric Analysis
SBRT Dosimetric AnalysisSBRT Dosimetric Analysis
SBRT Dosimetric Analysiscjhampton
 
Probationary officer performance appraisal
Probationary officer performance appraisalProbationary officer performance appraisal
Probationary officer performance appraisalrayvictor489
 
Bìa giáo án các loại.11
Bìa giáo án các loại.11Bìa giáo án các loại.11
Bìa giáo án các loại.11Hoàng Đoàn
 

Andere mochten auch (11)

Poster presentation
Poster presentationPoster presentation
Poster presentation
 
Monika Kopf_Abstract
Monika Kopf_AbstractMonika Kopf_Abstract
Monika Kopf_Abstract
 
PosterPresentations
PosterPresentationsPosterPresentations
PosterPresentations
 
Sbrt Volumetric Analysis
Sbrt Volumetric AnalysisSbrt Volumetric Analysis
Sbrt Volumetric Analysis
 
10879 Brochure
10879 Brochure10879 Brochure
10879 Brochure
 
SBRT Dosimetric Analysis
SBRT Dosimetric AnalysisSBRT Dosimetric Analysis
SBRT Dosimetric Analysis
 
WV-AS poster 2016
WV-AS poster 2016WV-AS poster 2016
WV-AS poster 2016
 
Probationary officer performance appraisal
Probationary officer performance appraisalProbationary officer performance appraisal
Probationary officer performance appraisal
 
Office-ONE-impression-Pilsen
Office-ONE-impression-PilsenOffice-ONE-impression-Pilsen
Office-ONE-impression-Pilsen
 
JUSTO A TIEMPO JIT
JUSTO A TIEMPO JITJUSTO A TIEMPO JIT
JUSTO A TIEMPO JIT
 
Bìa giáo án các loại.11
Bìa giáo án các loại.11Bìa giáo án các loại.11
Bìa giáo án các loại.11
 

Ähnlich wie Graham_FinalPoster

Professor Riccardo Polosa - E-Cigarette Summit 2014
Professor Riccardo Polosa - E-Cigarette Summit 2014Professor Riccardo Polosa - E-Cigarette Summit 2014
Professor Riccardo Polosa - E-Cigarette Summit 2014Neil Mclaren
 
Neurobiology and Treatment of Alcohol Withdrawal
Neurobiology and Treatment of Alcohol Withdrawal Neurobiology and Treatment of Alcohol Withdrawal
Neurobiology and Treatment of Alcohol Withdrawal Andri Andri
 
High-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPDHigh-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPDDr.Aslam calicut
 
Recommendations for Alcohol Withdrawal.final
Recommendations for Alcohol Withdrawal.finalRecommendations for Alcohol Withdrawal.final
Recommendations for Alcohol Withdrawal.finalDrew Reiter, RN
 
Research on Safety of Electronic Cigarettes - Dr. Konstantinos Farsalinos
Research on Safety of Electronic Cigarettes - Dr. Konstantinos FarsalinosResearch on Safety of Electronic Cigarettes - Dr. Konstantinos Farsalinos
Research on Safety of Electronic Cigarettes - Dr. Konstantinos FarsalinosLindsay Fox
 
HEALTH RELATED QUALITY OF LIFE OF HEAD AND NECK CANCER PATIENTS TREATED WITH ...
HEALTH RELATED QUALITY OF LIFE OF HEAD AND NECK CANCER PATIENTS TREATED WITH ...HEALTH RELATED QUALITY OF LIFE OF HEAD AND NECK CANCER PATIENTS TREATED WITH ...
HEALTH RELATED QUALITY OF LIFE OF HEAD AND NECK CANCER PATIENTS TREATED WITH ...CayoDental
 
Vision therapy in_adults_with_convergence.11
Vision therapy in_adults_with_convergence.11Vision therapy in_adults_with_convergence.11
Vision therapy in_adults_with_convergence.11Yesenia Castillo Salinas
 
Vision therapy in_adults_with_convergence.11
Vision therapy in_adults_with_convergence.11Vision therapy in_adults_with_convergence.11
Vision therapy in_adults_with_convergence.11Yesenia Castillo Salinas
 
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...Yesenia Castillo Salinas
 
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...Yesenia Castillo Salinas
 
Neuropharmacology: Nicotine
Neuropharmacology: NicotineNeuropharmacology: Nicotine
Neuropharmacology: NicotineBrian Piper
 
Yasser's covid 19 discrepancy phenomenon-dr. yasser mohammed hassanain elsayed
Yasser's covid 19 discrepancy phenomenon-dr. yasser mohammed hassanain elsayedYasser's covid 19 discrepancy phenomenon-dr. yasser mohammed hassanain elsayed
Yasser's covid 19 discrepancy phenomenon-dr. yasser mohammed hassanain elsayedYasserMohammedHassan1
 
MPET_Presentation
MPET_PresentationMPET_Presentation
MPET_PresentationAnant Naik
 
ICC Keynote Presentation 2013 N Ryan
ICC Keynote Presentation 2013 N RyanICC Keynote Presentation 2013 N Ryan
ICC Keynote Presentation 2013 N RyanNicole Ryan
 
ATAXIA CEREBELOSA__2.pdf
ATAXIA CEREBELOSA__2.pdfATAXIA CEREBELOSA__2.pdf
ATAXIA CEREBELOSA__2.pdfNatLes
 

Ähnlich wie Graham_FinalPoster (20)

Professor Riccardo Polosa - E-Cigarette Summit 2014
Professor Riccardo Polosa - E-Cigarette Summit 2014Professor Riccardo Polosa - E-Cigarette Summit 2014
Professor Riccardo Polosa - E-Cigarette Summit 2014
 
Neurobiology and Treatment of Alcohol Withdrawal
Neurobiology and Treatment of Alcohol Withdrawal Neurobiology and Treatment of Alcohol Withdrawal
Neurobiology and Treatment of Alcohol Withdrawal
 
High-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPDHigh-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPD
 
Recommendations for Alcohol Withdrawal.final
Recommendations for Alcohol Withdrawal.finalRecommendations for Alcohol Withdrawal.final
Recommendations for Alcohol Withdrawal.final
 
Research on Safety of Electronic Cigarettes - Dr. Konstantinos Farsalinos
Research on Safety of Electronic Cigarettes - Dr. Konstantinos FarsalinosResearch on Safety of Electronic Cigarettes - Dr. Konstantinos Farsalinos
Research on Safety of Electronic Cigarettes - Dr. Konstantinos Farsalinos
 
Dr konstantinos farsalinos the royal society 11 13
Dr konstantinos farsalinos the royal society 11 13Dr konstantinos farsalinos the royal society 11 13
Dr konstantinos farsalinos the royal society 11 13
 
Pituitary disease
Pituitary diseasePituitary disease
Pituitary disease
 
HEALTH RELATED QUALITY OF LIFE OF HEAD AND NECK CANCER PATIENTS TREATED WITH ...
HEALTH RELATED QUALITY OF LIFE OF HEAD AND NECK CANCER PATIENTS TREATED WITH ...HEALTH RELATED QUALITY OF LIFE OF HEAD AND NECK CANCER PATIENTS TREATED WITH ...
HEALTH RELATED QUALITY OF LIFE OF HEAD AND NECK CANCER PATIENTS TREATED WITH ...
 
Vision therapy in_adults_with_convergence.11
Vision therapy in_adults_with_convergence.11Vision therapy in_adults_with_convergence.11
Vision therapy in_adults_with_convergence.11
 
Vision therapy in_adults_with_convergence.11
Vision therapy in_adults_with_convergence.11Vision therapy in_adults_with_convergence.11
Vision therapy in_adults_with_convergence.11
 
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...
 
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...
Vision therapy in_adults_with_convergence_insufficiency_clinical_and_function...
 
Neuropharmacology: Nicotine
Neuropharmacology: NicotineNeuropharmacology: Nicotine
Neuropharmacology: Nicotine
 
Best practices
Best practicesBest practices
Best practices
 
The psychophysiology of tobacco use and craving
The psychophysiology of tobacco use and cravingThe psychophysiology of tobacco use and craving
The psychophysiology of tobacco use and craving
 
Yasser's covid 19 discrepancy phenomenon-dr. yasser mohammed hassanain elsayed
Yasser's covid 19 discrepancy phenomenon-dr. yasser mohammed hassanain elsayedYasser's covid 19 discrepancy phenomenon-dr. yasser mohammed hassanain elsayed
Yasser's covid 19 discrepancy phenomenon-dr. yasser mohammed hassanain elsayed
 
MPET_Presentation
MPET_PresentationMPET_Presentation
MPET_Presentation
 
ICC Keynote Presentation 2013 N Ryan
ICC Keynote Presentation 2013 N RyanICC Keynote Presentation 2013 N Ryan
ICC Keynote Presentation 2013 N Ryan
 
ATAXIA CEREBELOSA__2.pdf
ATAXIA CEREBELOSA__2.pdfATAXIA CEREBELOSA__2.pdf
ATAXIA CEREBELOSA__2.pdf
 
fentanyl or ketamine in EUS
fentanyl or ketamine in EUSfentanyl or ketamine in EUS
fentanyl or ketamine in EUS
 

Graham_FinalPoster

  • 1. RESEARCH POSTER PRESENTATION DESIGN © 2012 www.PosterPresentations.com On both days of testing, participants were subject to the oculomotor portion of the VNG assessment in addition to the spontaneous nystagmus assessment. •  Spontaneous Nystagmus: Focus on target for 10 seconds, then maintain gaze without fixation for 5 seconds. •  Gaze Evoked Nystagmus: Focus on target presented 15o from midline for 10 seconds, then maintain gaze for 5 seconds without fixation. Repeat in opposite direction. •  Saccades: Track 24 randomly presented targets which appear at either 5, 10, 20, -5, -10, or -20 degrees from midline. •  Smooth pursuit: Track at single target that passes repeatedly from left to right at frequencies of .10, .30, and .50 Hz •  Optokinetic nystagmus (OKN): Track targets in the center of a full-field presentation, moving at rates of 20, 40, and 60 deg/sec in both the clockwise and counterclockwise directions. Following completion of both test sessions, participants completed a caffeine withdrawal assessment to evaluate the degree to which they experienced seven of the most common symptoms of caffeine withdrawal. Participants 15 participants • 18-65 years of age • Normal visual acuity or corrected with contact lenses • No history of dizziness or balance disorders, seizure, tumors, multiple sclerosis, or cardio vascular disorders Caffeine Intake Assessment Prospective participants documented their caffeine consumption over a three- day time period and specified the type and amount of caffeine consumed. Individuals who were found to consume, on average, between 200 mg and 900 mg of caffeine per day were eligible to participate in the study. Data Collection Participants were assigned to one of two groups: •  Group A: subject to oculomotor testing immediately after caffeine consumption first, and once more after abstaining for 24 hours. •  Group B: tested after abstaining from caffeine for 24 hours first, and again immediately after caffeine consumption. Many vestibular testing centers require patients to abruptly abstain from caffeine intake prior to testing, a recommendation which does not appear to be evidence based. This study will examine the validity and necessity of this practice by investigating the effects of caffeine consumption and caffeine withdrawal on the oculomotor portion of the vestibular test battery, using videonystagmography. Findings that are in opposition to current test protocol trends may lead to the reevaluation of these protocols, which may be causing undue discomfort and inconvenience to the potential patient, and may also be negatively impacting test results. Caffeine is the most commonly used psychoactive drug in the world and is consumed daily by 85% of the United States population (Mitchell, Knight, Hockenberry, Teplansky, & Hartman, 2014; Nehlig, Daval, & Debry, 1992). Pharmacodynamically, caffeine has very positively reinforcing effects, however regular and heavy caffeine users may experience negative physical effects from abruptly abstaining from caffeine; this manifestation of symptoms is referred to as caffeine withdrawal. The following symptoms have been associated with caffeine withdrawal: headache, fatigue, decreased energy/activeness, decreased alertness, drowsiness, decreased contentedness, depressed mood, difficulty concentrating, irritability, and foggy headedness (Juliano & Griffiths, 2004). Caffeine withdrawal can occur after daily consumption of as little as 100 mg of caffeine; however, withdrawal symptoms tend to be more intense and more frequently reported with heavier caffeine use (Evans & Griffiths, 1999). Symptoms begin to occur between 6 and 43 hours after abstaining, with peak symptoms occurring around 24 hours (Ozsungur, Brenner, & El-Sohemy, 2009). Investigating the effect of caffeine on oculomotor assessment is an important undertaking because the tests of oculomotor function are known to be influenced by fatigue and inattention, as well as certain drugs that the patient may be taking (Jacobson & Shephard, 2008). It is useful to know how the fatigue and inattention associated with caffeine withdrawal may affect test results, as well as how caffeine consumption affects test results in regular users. Introduction and Background Methods Results Conclusions •  For most measures of the VNG oculomotor assessment there is no statistically significant difference in performance while under the influence of caffeine and after 24 hours of abstention. On average, all results fell within normal limits in both test conditions. •  Statistically significant differences were discovered for 40 deg/sec OKN performance, however, these differences would not be considered to be clinically significant. •  While 86% of participants reported experiencing caffeine withdrawal symptoms of drowsiness/fatigue and 80% reported decreased alertness/ concentration, these symptoms do not appear to have had a clinically significant impact on overall oculomotor assessment performance. •  The recommendation to have patients abstain from caffeine prior to VNG assessment does not appear to be necessary as caffeine did not produce a clinically significant effect on oculomotor performance in this study. Abrupt abstention from caffeine, however, does cause unpleasant caffeine withdrawal symptoms which can be a source of undue stress for the potential patient; these symptoms do not appear to significantly impact oculomotor test performance. References -Evans, S. & Griffiths, R. (1999). Caffeine withdrawal: A parametric analysis of caffeine dosing conditions. The Journal of Pharmacology and Experimental Therapeutics, 289(1), 285-294. -Jacobson, G., & Shepard, N. (2008). Balance function assessment and management. San Diego, CA: Plural Pub. -Juliano, L.M. & Griffiths, R.R. (2004). A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology, 176, 1-29. -Mitchel, D.C., Knight, C.A., Hockenberry, J., Teplansky, R., & Hartman, T.J. (2014). Beverage caffeine intakes in the U.S. Food and Chemical Toxicology, 63, 136-142. -Nehlig, A., Daval, J., & Debry, G. (1992). Caffeine and the central nervous system: Mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Research Reviews, 17, 139-170. -Ozsungur, S., Brenner, D., El-Sohemy, A. (2009). Fourteen well-described caffeine withdrawal symptoms facts into three clusters. Psychopharmacology, 201, 541-548 Department of Hearing, Speech, and Language Sciences – Gallaudet University, Washington, DC Krystyna N. Graham, M.S., and Chizuko Tamaki, Au.D., Ph.D The Effect of Caffeine Withdrawal on VNG Oculomotor Assessment* 4.95   2.19   4.90   5.28   1.57   3.38   0.00   1.00   2.00   3.00   4.00   5.00   6.00   .10  Hz   .30  Hz   .50  Hz   Average  Velocity  Gain  Asymmetry  (%)   Target  Frequency   Caffeinated    vs.  AbstenIon   Smooth  Pursuit  Asymmetry   Caffeinated   Absten/on   Results 0.18   0.17   0.18   0.18   0.18   0.18  0.18   0.17   0.17   0.23   0.17   0.17   0.00   0.05   0.10   0.15   0.20   0.25   5   10   20   -­‐5   -­‐10   20   Average  Saccade  Latency  (sec)   Target  Movement  from  Midline  (Degrees)   Caffeinated    vs.  AbstenIon     Saccade  Latency   Caffeinated   Absten/on   *Approved by the Gallaudet Institutional Review Board (IRB) Methods Results Figure 1. Comparison of overall saccade accuracy at each degree of target displacement, with caffeine and after abstention. Yellow circles indicate nearly statistical significant differences for the specified parameter (p =.086 for 10 degrees, p =.063 for -5 degrees). Figure 2. Comparison average saccade latency at each degree of target displacement, with caffeine and after abstention. Yellow circle indicates a nearly statistically significant difference for the specified parameter (p= .066 for -10 degrees). Figure 3. Average smooth pursuit velocity gain for rightward and leftward eye movements, with caffeine and after abstention. Yellow circle indicates a nearly statistically significant difference for the specified parameter (p =.089 for rightward gain at .10 Hz). Figure 4. Smooth pursuit velocity gain asymmetry, with caffeine and after abstention, in response to tracking sinusoidal targets presented at .10, .30, and .50 Hz. Figure 6. Average velocity gain of optokinetic nystagmus, with caffeine and after abstention, in response to clockwise and counterclockwise rotating stimuli presented at 20, 40, and 60 deg/ sec. Green circle indicates statistically significant difference for the specified parameter (p = .041 for 40 deg/sec clockwise stimuli). Figure 5. Graphic representation of the average velocity of optokinetic nystagmus, with caffeine and after abstention, in response to clockwise and counterclockwise rotating stimuli presented 20, 40, and 60 deg/sec. Green circles indicate statistically significant differences for the specified parameters (p = .009 for 40 deg/sec clockwise; p = .013 for 40 deg/sec counterclockwise). 22.71   37.63   40.27   20.26   32.85   35.53   23.43   34.18   37.53   17.40   29.63   33.41   0.00   5.00   10.00   15.00   20.00   25.00   30.00   35.00   40.00   45.00   20  Deg/Sec   40  Deg/Sec   60  Deg/Sec   20  Deg/Sec   40  Deg/Sec   60  Deg/Sec   Clock  Wise  S/mulus   Counterclockwise  S/mulus   Average  Velocity  (Deg/Sec)     Caffeinated  vs.  AbstenIon   OKN  Velocity     Caffeinated   Absten/on   1.00   0.85   0.60   1.00   0.81   0.58   0.75   0.55   0.75   0.57   0   0.2   0.4   0.6   0.8   1   1.2   20  Deg/Sec   40  Deg/Sec   60  Deg/Sec   20  Deg/Sec   40  Deg/Sec   60  Deg/Sec   Clock  Wise  S/mulus   Counterclockwise  S/mulus   Average  Velocity  Gain   Caffeinated  vs.  AbstenIon   OKN  Gain   Caffeinated   Absten/on   0.93   0.96   0.91   0.95   0.97   0.90  0.90   0.98   0.96   0.92   0.98   0.94   0.86   0.88   0.9   0.92   0.94   0.96   0.98   1   .10  Hz   .30  Hz   .50  Hz   .10  Hz   .30  Hz   .50  Hz   Gain  LeU     Gain  Right   Average  Velocity  Gain     Caffeinated    vs.  AbstenIon   Smooth  Pursuit  Velocity  Gain     Caffeinated   Absten/on   96.91   102.52   95.13   98.70   97.29   97.05   99.80   97.74   94.80   96.42   98.99   97.96   90.00   92.00   94.00   96.00   98.00   100.00   102.00   104.00   5   10   20   -­‐5   -­‐10   -­‐20   Overall  Accuracy  (%)   Target  Movement  from  Midline  (Degrees)   Caffeinated    vs.  AbstenIon      Saccade  Accuracy   Caffeinated   Absten/on   0   2   4   6   8   10   12   14   16   Normal   Sqaurewave  Jerk   DriU   Normal   Sqaurewave  Jerk   DriU   Absten/on  Caffeinated   Total  Number  of  ParIcipants   QualitaIve  Finding   FixaIon  On   Spontaneous   Gaze  LeU   Gaze  Right   0   2   4   6   8   10   12   14   16   Normal   Sqaurewave  Jerk   DriU   Normal   Sqaurewave  Jerk   DriU   Absten/on  Caffeinated   Total  Number  of  ParIcipants   QualitaIve  Finding   FixaIon  Off   Spontaneous   Gaze  LeU   Gaze  Right   Figure 7a. Qualitative results of gaze and spontaneous evoked nystagmus assessments with fixation light on, caffeinated and after abstention. Figure 7b. Qualitative results of gaze and spontaneous evoked nystagmus assessments with fixation light off, caffeinated and after abstention. Figure 8. Caffeine withdrawal assessment responses.